Compare Sterling Biotech with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs CIPLA - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH CIPLA STERLING BIOTECH/
CIPLA
 
P/E (TTM) x -0.4 31.9 - View Chart
P/BV x 0.0 4.5 0.3% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 STERLING BIOTECH   CIPLA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
CIPLA
Mar-20
STERLING BIOTECH/
CIPLA
5-Yr Chart
Click to enlarge
High Rs11586 1.8%   
Low Rs3357 1.0%   
Sales per share (Unadj.) Rs26.8207.0 12.9%  
Earnings per share (Unadj.) Rs-15.018.6 -80.4%  
Cash flow per share (Unadj.) Rs-5.533.2 -16.5%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs54.9195.5 28.1%  
Shares outstanding (eoy) m267.87806.35 33.2%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x0.32.3 11.4%   
Avg P/E ratio x-0.525.3 -1.8%  
P/CF ratio (eoy) x-1.314.2 -9.0%  
Price / Book Value ratio x0.12.4 5.3%  
Dividend payout %021.5 0.0%   
Avg Mkt Cap Rs m1,862379,912 0.5%   
No. of employees `0001.425.8 5.2%   
Total wages/salary Rs m54730,270 1.8%   
Avg. sales/employee Rs Th5,303.36,459.6 82.1%   
Avg. wages/employee Rs Th403.81,171.2 34.5%   
Avg. net profit/employee Rs Th-2,959.0580.2 -510.0%   
INCOME DATA
Net Sales Rs m7,181166,949 4.3%  
Other income Rs m433,442 1.2%   
Total revenues Rs m7,223170,391 4.2%   
Gross profit Rs m94732,060 3.0%  
Depreciation Rs m2,54311,747 21.7%   
Interest Rs m4,3771,974 221.8%   
Profit before tax Rs m-5,93121,782 -27.2%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9246,312 -30.5%   
Profit after tax Rs m-4,00714,995 -26.7%  
Gross profit margin %13.219.2 68.7%  
Effective tax rate %32.429.0 112.0%   
Net profit margin %-55.89.0 -621.2%  
BALANCE SHEET DATA
Current assets Rs m14,335117,038 12.2%   
Current liabilities Rs m49,80943,931 113.4%   
Net working cap to sales %-494.043.8 -1,128.2%  
Current ratio x0.32.7 10.8%  
Inventory Days Days40396 421.4%  
Debtors Days Days17185 200.6%  
Net fixed assets Rs m55,432107,424 51.6%   
Share capital Rs m2681,613 16.6%   
"Free" reserves Rs m13,935156,018 8.9%   
Net worth Rs m14,701157,630 9.3%   
Long term debt Rs m9,47823,693 40.0%   
Total assets Rs m73,988236,626 31.3%  
Interest coverage x-0.412.0 -2.9%   
Debt to equity ratio x0.60.2 428.9%  
Sales to assets ratio x0.10.7 13.8%   
Return on assets %0.57.2 7.0%  
Return on equity %-27.39.5 -286.5%  
Return on capital %-6.412.8 -50.0%  
Exports to sales %25.933.0 78.4%   
Imports to sales %0.20-   
Exports (fob) Rs m1,86055,175 3.4%   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86056,036 3.3%   
Fx outflow Rs m256,764 0.4%   
Net fx Rs m1,83549,272 3.7%   
CASH FLOW
From Operations Rs m1,71930,685 5.6%  
From Investments Rs m-3,1481,040 -302.6%  
From Financial Activity Rs m1,426-29,488 -4.8%  
Net Cashflow Rs m-32,340 -0.1%  

Share Holding

Indian Promoters % 33.9 16.0 211.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.0 12.2 -  
FIIs % 9.9 23.7 41.8%  
ADR/GDR % 16.9 1.1 1,536.4%  
Free float % 39.3 26.2 150.0%  
Shareholders   21,482 161,166 13.3%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ALEMBIC PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT PHARMOVA   BIOCON   

Compare STERLING BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - SUVEN LIFE SCIENCES COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS